Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
5
×
clinical trials
life sciences
national blog main
boston top stories
boston
drugs
new york blog main
alnylam pharmaceuticals
biotech
national top stories
new york
new york top stories
rna interference
san diego blog main
san francisco blog main
accelerated approval
acute hepatic porphyria
aldehyde
aldeyra therapeutics
alirocumab
allergan
allergic conjunctivitis
amgen
aminolevulinic acid
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bluebird bio
bristol-myers squibb
clinical data
dry eye disease
duchenne muscular dystrophy
dyne therapeutics
evercore isi
evolocumab
facioscapulohumeral muscular dystrophy
gene therapy
genfit
What
data
5
×
drug
5
×
new
medicine
alnylam
long
medicines
pharmaceuticals
rna
therapeutics
ago
aldeyra
approved
based
biotechs
cholesterol
cleared
closer
considering
disclosed
disease
diseases
dyne
early
evidence
expected
experimental
eye
eyes
far
fatty
fda
fighting
filing
genetic
having
heart
horizon
humans
inflammation
Language
unset
Current search:
drug
×
data
×
" boston blog main "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug